NCT07318636 2026-01-06
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 1 Not yet recruiting
Clinical Trials
13 trialsNCT07288034 2025-12-17
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT06512207 2025-09-09
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Jinzhou Medical University
Phase NA Recruiting
NCT06357598 2024-04-10
PILOT
The Affiliated Hospital of Qingdao University
Phase 4 Recruiting
NCT03393858 2024-02-07
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Capital Medical University
Phase 1/2 Terminated
NCT04422392 2023-08-30
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Terminated
NCT04793815 2023-06-29
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Completed
NCT05605613 2022-11-09
PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial
The First Affiliated Hospital of Zhengzhou University
Phase 2/3 Unknown
NCT04459611 2022-07-12
neoSCORE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04943029 2021-09-02
NEOSUN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04790539 2021-03-10
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT03945227 2020-10-19
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
Yonsei University
Phase 2 Withdrawn
NCT02466568 2019-09-09
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn